We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agennix Announces Data From Talactoferrin Phase II Trial in Severe Sepsis
News

Agennix Announces Data From Talactoferrin Phase II Trial in Severe Sepsis

Agennix Announces Data From Talactoferrin Phase II Trial in Severe Sepsis
News

Agennix Announces Data From Talactoferrin Phase II Trial in Severe Sepsis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agennix Announces Data From Talactoferrin Phase II Trial in Severe Sepsis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agennix AG has announced that new and more detailed data from a Phase II trial in severe sepsis with talactoferrin, an oral biologic therapy with immunomodulatory and antibacterial properties, will be presented at the 40th Critical Care Congress of the Society of Critical Care Medicine, to be held January 15-19, 2011 in San Diego, California.

Talactoferrin-related presentations are as follows:

"Talactoferrin alfa reduces 3 and 6 month all-cause mortality in patients with severe sepsis," will be part of the oral session, "Infectious Disease-Sepsis," to be held on January 16, 2011, 3:00-5:00 PM.

"Talactoferrin may confer increased survival in patients with septic shock and systolic cardiac dysfunction," will be presented as a poster presentation in the Therapeutics-Drugs and Pharmacokinetics-2 category.

Advertisement